饮酒与递增的心脏代谢危险因素和肝病的关联:一项全国横断面研究
该研究基于美国国家健康与营养调查(NHANES)2001年1月至2020年3月数据,纳入40,898名年龄≥20岁且饮酒和心脏代谢危险因素(CMRF)状态完整的参与者,分析饮酒量增加(女性≥140克/周、男性≥210克/周)与CMRF数量对高FIB-4(>2.67)的影响。结果显示,在饮酒量增加者中,CMRF数量≥3与高FIB-4风险约2倍相关,而糖尿病、高腰围和高血压与显著肝纤维化相关,血脂异常则不相关;作者认为将MetALD分层为≥3个CMRF可能比1个CMRF提供更优的纤维化分层。
要点
- 饮酒量增加者中,CMRF数量≥3个与高FIB-4风险约2倍相关(vs 0个CMRF)。
- 饮酒量增加者中,糖尿病、高腰围和高血压与显著肝纤维化相关,血脂异常不相关。
- 饮酒量增加者中,以≥3个CMRF区分高FIB-4概率的截断值最优。
核心结论
- 将MetALD分层为≥3个CMRF而非1个CMRF,可能提供更优的纤维化分层。
- 在饮酒量增加者中,糖尿病、高腰围和高血压与显著肝纤维化相关,但血脂异常不相关。
研究设计与样本
- 全国横断面研究,使用美国国家健康与营养调查(NHANES)2001年1月至2020年3月数据。
- 纳入年龄≥20岁且饮酒和CMRF状态完整的参与者40,898名。
- CMRF按美国国家胆固醇教育计划成人治疗组III定义;饮酒量增加定义为女性≥140克/周、男性≥210克/周。
- 主要结局为FIB-4>2.67。
主要发现
- 饮酒量增加者2282名,无饮酒量增加者38,616名。
- 在CMRF数量为0、1、2、3、4或5个时,饮酒量增加者高FIB-4患病率均高于无饮酒量增加者:0个(2.3%;95%CI 1.0%-5.0% vs 0.7%;95%CI 0.5%-0.9%)、1个(3.0%;95%CI 1.6%-5.6% vs 1.7%;95%CI 1.4%-2.1%)、2个(3.3%;95%CI 2.1%-5.1% vs 2.1%;95%CI 1.8%-2.4%)、3个(5.9%;95%CI 3.5%-9.6% vs 2.5%;95%CI 2.1%-2.9%)、4或5个(6.1%;95%CI 3.3%-9.7% vs 4.0%;95%CI 3.5%-4.5%)。
- 在饮酒量增加者中,多变量logistic回归显示,与0个CMRF相比,3个CMRF(aOR 2.57;95%CI 0.93-7.08)和4或5个CMRF(aOR 2.64;95%CI 1.05-6.67)与高FIB-4风险约2倍相关,而1个(aOR 1.24;95%CI 0.41-3.69)或2个(aOR 1.39;95%CI 0.56-3.50)CMRF无显著关联。
关键数值与推荐
- 饮酒量增加定义为女性≥140克/周、男性≥210克/周。
- 高FIB-4定义为FIB-4>2.67。
- 在饮酒量增加者中,基于敏感度/特异度的欧几里得距离提示,区分高FIB-4较高概率的最佳截断值为≥3个CMRF。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: New nomenclature allows a single cardiometabolic risk factor (CMRF) with alcohol to classify metabolic dysfunction-associated steatotic liver disease (MASLD) and with "increased alcohol intake" (MetALD), which is controversial because alcohol causes CMRFs. Studies regarding incremental CMRFs and liver-related outcomes among alcohol users would be informative. METHODS: Using the National Health and Nutrition Examination Survey (NHANES) (1/2001-3/2020), we included participants aged ≥20 years with complete alcohol and CMRF status. CMRFs were defined by the National Cholesterol Education Program's Adult Treatment Panel III. Increased alcohol use corresponded to ≥140 g/week (women)/≥210 g/week (men). The primary outcome was Fibrosis-4 (FIB-4) >2.67. RESULTS: Among 40,898 participants, 2282 had increased vs 38,616 without increased alcohol use. Prevalence of high FIB-4 among increased vs without increased alcohol use was higher at each quantity of CMRFs, and with each incremental CMRF: 0 (2.3%; 95% confidence interval [CI], 1.0%-5.0% vs 0.7%; 95% CI, 0.5%-0.9%), 1 (3.0%; 95% CI, 1.6%-5.6% vs 1.7%; 95% CI, 1.4%-2.1%), 2 (3.3%; 95% CI, 2.1%-5.1% vs 2.1%; 95% CI, 1.8%-2.4%), 3 (5.9%; 95% CI, 3.5%-9.6% vs 2.5%; 95% CI, 2.1%-2.9%), and 4 or 5 (6.1%; 95% CI, 3.3%-9.7% vs 4.0%; 95% CI, 3.5%-4.5%) CMRFs. Among increased alcohol users, in multivariable logistic regression, 3 (adjusted odds ratio [aOR], 2.57; 95% CI, 0.93-7.08), 4 or 5 (aOR, 2.64; 95% CI, 1.05-6.67) CMRFs were associated with 2-fold higher odds of high FIB-4 (vs 0 CMRFs), but not 1 (aOR, 1.24; 95% CI, 0.41-3.69) or 2 (aOR, 1.39; 95% CI, 0.56-3.50) CMRFs. Among individuals with increased alcohol use, sensitivity/specificity-based Euclidean distance suggested an optimal cutoff of ≥3 CMRFs to differentiate higher probability of high FIB-4. CONCLUSIONS: Stratifying MetALD as ≥3 CMRFs, rather than 1 CMRF, may provide more optimal fibrosis stratification. Diabetes, high waist circumference, and hypertension are associated with significant liver fibrosis among individuals with increased alcohol use, but not dyslipidemia.
引用
- Lee BP, Molina J, Kim S, et al. Association of Alcohol and Incremental Cardiometabolic Risk Factors With Liver Disease: A National Cross-sectional Study. Clin Gastroenterol Hepatol. 2025. PMID: 39909281. doi:10.1016/j.cgh.2025.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。